Clinical Trials Directory

Trials / Completed

CompletedNCT03034980

Influence of Training Intensity in Coronary Artery Disease

Influence of Training Intensity on Exercise Capacity and Risk Profile in Coronary Artery Disease

Status
Completed
Phase
Study type
Observational
Enrollment
343 (estimated)
Sponsor
Hasselt University · Academic / Other
Sex
All
Age
25 Years – 90 Years
Healthy volunteers
Not accepted

Summary

Coronary artery disease (CAD) is associated with high mortality worldwide. Narrowing of the coronary arteries can cause an acute myocardial infarction. Patient with cardiac ischemia are often treated with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). Following hospitalisation, the patients are offered to attend a classical rehabilitation program with moderate exercise intensity. Current exercise program for cardiac rehabilitation has proven to reduce cardiovascular risk factors 1. Is it possible to improve the exercise capacity and risk profile even more if the exercise program includes more vigorous training? The program starts one week after the cardiac incident (AMI, PCI or CABG) and takes 12 weeks to complete. Patients with heart failure and valvular disease are excluded. First ventilatory threshold (VT1) and second ventilatory threshold (VT2) are determined during cycloerometry. VT2 reflects aerobic-anaerobic transition and therefore the aerobic functional capacity2. Exercise load reached at VT2 is used to determine the training load during rehabilitation. The research goal is to investigate the influence of training intensity on the exercise capacity and risk profile of CAD patients.

Conditions

Interventions

TypeNameDescription
OTHERTraining intensity (workload) during ergospirometryThe reached workload (W) during each training is noted during 12 weeks of rehabilitation. The relative intensity is expressed as a percentage of VT1 and VT2.

Timeline

Start date
2016-12-20
Primary completion
2017-07-01
Completion
2017-09-15
First posted
2017-01-27
Last updated
2018-02-27

Locations

1 site across 1 country: Belgium

Source: ClinicalTrials.gov record NCT03034980. Inclusion in this directory is not an endorsement.